Q-omics provides the consensus-scored RBBP4P5 profile across patient tissues and cancer cell-line models. RBBP4P5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RBBP4P5 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RBBP4P5 RNA expression shows 9,346 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where RBBP4P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBBP4P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBBP4P5 survival associations across molecular data types. RBBP4P5 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBBP4P5 RNA expression–survival associations across cancer types. High RBBP4P5 expression shows unfavorable associations in LGG, ACC and LIHC, but favorable associations in KIRC, PAAD and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify KIRC as the clearest survival context for RBBP4P5 RNA expression.
This table summarizes RBBP4P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RBBP4P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBBP4P5 shows higher tumor expression in COAD, LUAD, HNSC, LIHC and STAD. The COAD box plot shows higher RBBP4P5 RNA expression in tumor versus normal tissue (log2 FC = +0.122, t-test p = .004).
This table shows molecular features associated with RBBP4P5 in patient tissues and cancer cell lines. In patient samples, RBBP4P5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
